Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).

Mickle continued, "The next clinical milestone for KP201 will be the completion of oral and intranasal abuse liability studies in the first quarter of 2014.  These studies will be important indicators of KP201's unique abuse-deterrent capabilities, which we believe are unlike any prescription opioid on the market or in development."

About KemPharm

KemPharm is abiopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the third quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle


Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.


SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products ... CSM-C 600 compact clean steam generator . This unit is a skid ... of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can produce up ...
(Date:10/12/2015)... October 12, 2015 cell surface marker ... by 2022, according to a new report by Grand View ... rise in incidence of oncology diseases and other cell-associated disorders. ... expected to reach USD 6.49 billion by 2022, according to ... in demand can be attributed to rise in incidence of ...
(Date:10/12/2015)... 12, 2015 LabStyle Innovations Corp. ... Solution, today announced its Medical Director, Dr. Moshe ... MobiHealth,s 5th EAI International Conference on Wireless Mobile ... innovations in mobile and wireless technologies," the conference will ... from October 14 - 16, 2015. The conference is ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a ... retinal diseases that can safely and chronically be administered as an eye drop, announced ... co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at ...
Breaking Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
(Date:9/10/2015)... -- Pursuant Health has collaborated with health experts ... image-based health risk assessment (HRA) optimized for Pursuant ... assessment quantifies user results into an easily understood ... biological age based on personal health habits, characteristics ... Comprised of age, gender, and risk ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
Breaking Biology News(10 mins):